You are here

Development of a novel clinical assay for measuring serum hepcidin levels

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK101264-01
Agency Tracking Number: R43DK101264
Amount: $276,193.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PO BOX 14650
RESEARCH TRIANGLE PARK, NC 27709-4650
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SHRIKUMAR NAIR
 (919) 433-2268
 snair@affinergy.com
Business Contact
 CHRIS BRASFIELD
Phone: (919) 433-2227
Email: cbrasfield@affinergy.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Hepcidin is the peptide hormone responsible for regulating circulating iron concentrations. Overexpression of hepcidin results in severe iron deficiency and anemia, whereas hepcidin deficiency leads to iron overload. Not surprisingly, abnormalities in hepcidin production and circulating concentrations are highly correlated with various disease states such as renal disease, cancer, hereditary hemochromatosis (HH), hypoxia, anemia of inflammation, infection, inflammatory diseases, and heart disease. Accurate methods for detecting hepcidin in serum will lead to improvements in our understanding, diagnosis, and clinical management of iron metabolism disorders. Unfortunately, there is no FDA approved assay for measuring hepcidin levels in serum. The development of a clinically relevant hepcidin assay has been hindered by hepcidin's very low immunogenicity, making it extremely challenging to produce antibodies against the hormone. The few immunoassays that do exist are poor

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government